Harry is the Research Development Director of the Institute of Biomedical Engineering, where he coordinates multidisciplinary research initiatives in the medical technology field. He works with academics across College to foster new collaborations and advance research activities at the interface of biomedical sciences and engineering, and to translate novel technologies in partnership with clinical investigators, Med-Tech companies and Imperial Innovations. As part of his role he is programme manager for the Medical Engineering Solutions in Osteoarthritis Centre of Excellence.
Previously, Harry was Director of Business Development and Company Secretary at Oxford BioTherapeutics, an emerging biotech company located in Oxford, UK and San Jose, CA, focussed on cancer target / biomarker discovery and the development of novel antibody-based drugs for cancer. During five years at the company he completed numerous major collaboration and licensing agreements with global biopharmaceutical and diagnostics companies (including GSK, Sanofi, Amgen, BMS, Seattle Genetics, Alere & Menarini).
In his earlier career as a research scientist, Harry completed a PhD and post-doctoral research on the industrial application of thermostable enzymes at the University of Bath and worked for companies in the fields of genomics, biomanufacturing and scientific software development. Harry has an MBA from Cranfield School of Management.